Price Chart

Profile

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
URL https://www.modernatx.com
Investor Relations URL https://investors.modernatx.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Feb. 21, 2025 (est.)
Last Earnings Release Nov. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
URL https://www.modernatx.com
Investor Relations URL https://investors.modernatx.com/
HQ State/Province Massachusetts
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Feb. 21, 2025 (est.)
Last Earnings Release Nov. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A